Abstract
Advanced prostate cancer includes a wide spectrum of disease ranging from hormone naïve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or abiraterone acetate to ADT results in significant survival advantage as compared with ADT alone. Furthermore, in non-metastatic castration-resistant prostate cancer (M0 CRPC), two second-generation anti-androgens, apalutamide and enzalutamide, when used in combination with ADT, have demonstrated a significant benefit in metastasis-free survival. Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference37 articles.
1. Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014.;J Li;Ann Epidemiol.,2018
2. Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.;C Steele;Cancer.,2017
3. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.;R Marques;PLoS One.,2010
4. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.;W Harris;Nat Clin Pract Urol.,2009
5. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.;C Huggins;CA Cancer J Clin.,1972
Cited by
80 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献